National comparative audit of patient information and consent for transfusion 2014: comparison of practice between clinical specialities : 1
Excellent outcome for adults and older adolsecents following reduced intensity allogeneic haematopoietic stem cell transplantation for inherited primary immune deficiencies (PID) : 2
Haemostatic changes, transfusion management and clinical outcomes of obstetric massive transfusion cases in the UK : 3
Role of platelet coordinator in stewardship of platelet transfusion : 4
Why is transfusion-associated circulatory overload (TACO) under-reported? : 5
Challenging transfusion practice: significant reduction in red cell transfusions in medical patients through behavioural interventions : 6
Emergency O negative red cells for women - defining the age of cut off for ‘child bearing potential’ : 7
Targeted next-generation sequencing reveals mutational complexity of familial platelet disorder with predisposition to acute myeloid leukaemia : 8
The autophagy related protein ATG7 regulates differentiation and energy metabolism of CML cells : 9
Pacritinib suppresses leukaemic outgrowth from stroma-adherent primary AML cells harbouring FLT3-ITD : 10
Treatment of essential thrombocythaemia in Europe: an observational study of 3649 high-risk patients in EXELS : 11
Immunological profile of patients after HSCT using the FCC conditioning regimen for treatment of severe aplastic anemia indicates potential basis for tolerance with mixed T-cell chimerism and extremely low incidence of GvHD : 12
Donor lymphocyte infusion - a retrospective single centre audit : 13
The observed incidence of cardiovascular ischemic events in dasatinib-treated patients in clinical trials compared with the expected incidence based on general external populations : 14
A single-centre experience of treating adult patients with Langerhans’ cell histiocytosis and Erdheim Chester disease: sustained response to oral methotrexate in frontline and relapsed disease : 15
Effects of rivaroxaban on routine tests of haemostasis as determined with a full range of reagents: results of a UK NEQAS exercise : 16
Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome : 17
Idarucizumab, a specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in elderly and renally impaired subjects : 18
Whole genome sequencing and inherited diseases of the blood stem cell and its progeny : 19
Oral anticoagulant agent-associated bleeding events reporting system (ORANGE) study : 20
The FVIII:C to VWF:Ag ratio in patients with von Willebrand disease type I may indicate co-inheritance of F8 or VWF 2N variants : 21
ThromboGenomics: next generation sequencing to diagnose inherited bleeding, thrombotic and platelet disorders : 22
Iron status in paediatric acute lymphoblastic leukaemia : 23
Quantitative PCR using patient specific primers detects occult central nervous system involvement in more than one-third of children with acute lymphoblastic leukaemia : 24
Central venous line placement prior to induction therapy in children with acute lymphoblastic leukaemia does not increase the risk of line-related thrombosis : 25
The presence of non-tumour T and B lymphocytes in diagnostic bone marrow is associated with improved overall survival in childhood common acute lymphoblastic leukaemia : 26
SPIRIT 2: an NCRI randomised study comparing dasatinib with imatinib in patients with newly diagnosed chronic myeloid leukaemia - 2 year follow up : 27
Haemoglobinopathy survey - a picture of transfusion for sickle cell disease and thalassaemia in 11 London hospitals : 28
In-vivo studies of trafficking in chronic lymphocytic leukaemia provide definitive evidence of re-entry into the lymph-node compartment and suggest the existence of a quiescent sub-clone : 29
APL of all risk groups is highly curable with a chemo-free combination of attenuated arsenic trioxide and ATRA : 30
Discovery of novel genes underlying inherited bleeding and platelet disorders by genome sequencing : 31
Childhood pre-B acute lymphoblastic leukaemia cells capable of central nervous system engraftment are common, heterogeneous and transit the blood-cerebrospinal fluid barrier : 32
Leukaemia-associated somatic mutations drive distinct patterns of age-related clonal haemopoiesis : 33
Second interim analysis of a phase 3 study of idelalisib plus rituximab (R) for relapsed chronic lymphocytic leukaemia (CLL): efficacy analysis in patient subpopulations with Del(17p) and other adverse prognostic factors : 34
Updated efficacy including subgroup analyses and safety in the phase 3 RESONATETM trial of ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukaemia/small lymphocytic lymphoma : 35
Interim results from ASPIRE, a randomized, open-label, multicenter phase 3 study evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma : 36
Dual mTOR inhibition is an effective therapeutic approach for reducing tumour load in chronic lymphocytic leukaemia : 37
Mature follow up from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)- refractory indolent B-cell non-Hodgkin lymphoma (iNHL) : 38
Phase 2a study of copanlisib, a novel phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with relapsed/refractory, idolent or aggressive lymphoma : 39
Nocturnal desaturation and proteinuria in children with sickle cell anaemia : 40
R2 MRI quantification of hepatic iron: an additional tool in the management of patients with HFE gene mutations : 41
Review of regular automated red cell exchange transfusions and the associated risk of iron overload in patients with sickle cell disease : 42
Transcranial Doppler screening and residual stroke rate in UK children with sickle cell disease: data from the East London and Essex clinical haemoglobinopathy network : 43
Identifying and characterizing spontaneous cerebrovascular disease in a murine model of human sickle cell disease : 44
A prospective ‘live’ audit of a community-based electronic haematology advice service for GPs : 45
Epidemiological research on Hodgkin lymphoma in Morocco : 46
A survey of regional anaesthetic practice in immune and gestational thrombocytopenia in pregnancy : 47
Assessing the care experiences of people living with sickle cell disease to inform the development of a patient reported experience measure (PREM) : 48
Audit of the use of chest X-rays in the management of adult neutropenic sepsis at King's College Hospital, London : 49
Introduction of a regional apheresis roadmap: experience from the North West of England and North Wales : 50
Anticoagulation in patients undergoing cardioversion at Hampshire Hospitals NHS Foundation Trust : 51
A study of the implementation of romiplostim & eltrombopag in the NHS in England : 52
Evaluation of the body fluid mode on the XE-5000 for counting leukocytes in bronchoalveolar lavage fluid : 53
Bone marrow trephines ≥12 mm adequate when reported in an integrated diagnostic service : 54
The impact of formal chemotherapy training on haematology registrars : 55
Formalising palliative care education augments clinical skills in haematology trainees : 56
A retrospective audit of send-away haematological malignancy diagnostic tests at a District General Hospital highlights the importance of local guidelines to reduce inappropriate testing : 57
Idiopathic systemic capillary leak syndrome treated successfully with maintenance intravenous immunoglobulin : 58
Management of the ‘Choose and Book’ system for polycythaemia/thrombocytosis by the MPN specialist nurse : 59
A single centre review of the use and outcomes of cranial imaging for in-patients with haematological malignancies : 60
The development and review of performance assessment scoring in blood films for parasites external quality assessment : 61
Second line treatment for immune thrombocytopenia (ITP): a review of patients with immune thrombocytopenia in Basildon Hospital : 62
Carbapenem resistant gram negative organisms as emerging pathogens in neutropenic fever : 63
Integration of haemato-oncology and palliative care services and staff perceptions to referral : 64
A survey of genetic haemochromatosis testing pattern in a tertiary centre : 65
Autologous 111In- labelled platelet scan as a predictor of splenectomy outcome in ITP : 66
An email advice service for non-urgent general practitioners’ haematological queries : 67
Hickman line infection rates, causative organisms and impacts on recurrence - a retrospective analysis at the James Cook University Hospital, Middlesbrough : 68
Management of anaemia in a resource limited setting: an observational study of current practice at Queen Elizabeth Central Hospital, Malawi : 69
Quality improvement project: pre-printed drug labels to improve patient safety on a large haematology unit : 70
A virtual learning environment: an innovative high quality tool to provide laboratory training in haematology : 71
New conclusions in scintigraphy: results of sickle cell disease bone involvements : 72
A regional review of maternal thrombocytopenia : 73
Does trans-cutaneous electrical nerve stimulation (TENS) alleviate the pain experienced during bone marrow sampling in addition to standard techniques? A randomised, double-blinded, controlled trial : 74
Managing paroxysmal nocturnal haemoglobinuria (PNH) in pregnancy in the eculizumab era: a case series : 75
Annual British Society for Haematology confidential survey of bone marrow examination associated adverse events 2013 : 76
Halving the number of tests to differentiate iron deficiency anaemia from anaemia of chronic disease : 77
Blood cultures and antibiotics sensitivities in haematology patients : 78
An audit of the initial assessment of aplastic anaemia in a single region : 79
A review of central line-associated bloodstream infections in adult haematology patients in a BCSH level 3 district general hospital : 80
The use of thrombopoeitin (TPO) in the clinical diagnosis of immune thrombocytopenia (ITP) : 81
The effects of Triton-X on haematological assays when used as an inactivator for Ebola virus : 82
A case report may lead to addendum to BSH treatment guideline of acquired VWD : 83
The importance of determining other possible inherited explanations for an elevated ferritin other than type 1 hereditary haemochromatosis: when not to venesect your patient : 84
Refractory atypical Rosai-Dorfman disease (RDD) successfully treated according to a Langerhans cell histiocytosis regimen : 85
Venous thromboembolism (VTE) in hospitalised non-surgical cancer patients and its burden on healthcare in an Asian tertiary hospital : 86
Recurrence of VTE over 4 years: local outcome data to determine and compare location of VTE events for hospital or community acquired VTE : 87
Direct oral anti-coagulants for prevention of stroke and systemic embolism in non-valvular atrial fibrillation - Barts Health experience across two sites : 88
Systemic therapy in acquired haemophilia A: a single institute experience : 89
A double-centre retrospective study into rates of postpartum haemorrhage in women on low molecular weight heparin : 90
Acute nurse-led VTE service reduces admission and facilitates NOAC use for VTE : 91
Accuracy of published FVIII/FIX:C assay result times: implications for pharmacokinetic (PK) guided dose predictions: a UK-PK study pilot : 92
Audit of the effect of the introduction of a guideline for the management of superficial vein thrombosis to a nurse-led DVT clinic : 93
Evaluation of pathology quality assurance review recommendations: Data from a UK NEQAS for Blood Coagulation (UK NEQAS BC) questionnaire : 94
Quality and predictors of anticoagulation with Warfarin in atrial fibrillation patients : 95
Investigation to determine the miRNA profile and their functional properties in erythrocytes : 96
Characteristics of patients with factor IX Leyden from a single centre : 97
Measuring safety outcomes after lower limb orthopaedic surgery: are we improving outcomes? : 98
Review of factor XI deficiency: bleeding phenotype and clnical considerations : 99
Trends in diagnosis and mortality from thrombotic thrombocytopenic purpura in England from 2003 to 2013: are we improving outcomes? : 100
Higher Warfarin dosage of above 10 mg leads to lower time in therapeutic range : 101
A case of heparin-induced thrombocytopenia with thrombosis and cross-reacting antibodies to fondaparinux successfully treated with rivaroxaban : 102
Cancer-associated VTE occurring over 1 year in a small district general hospital : 103
Patients with suspected TTP should be acutely managed in a critical care setting : 104
A study of DOAC awareness indicating inadequate recognition with potential for patient harm : 105
Inferior vena cava agenesis - an unusual cause of unprovoked deep vein thrombosis presenting with characteristic features in young patients : 106
New UKHCDO von Willebrand disease guidelines allow re-classification of a large proportion of adult patients and can result in de-diagnosis of patients without haemorrhagic consequences : 107
Thrombopoietin-receptor agonists in immune thrombocytopaenic purpura: our experience at East Kent Hospitals University NHS Foundation Trust : 108
The effect on standard haemostasis assays in patients receiving apixaban : 109
Effects of Apixaban on routine tests of haemostasis as determined with a full range of reagents: results of a UK NEQAS exercise : 110
Low incidence of VTE but with high early mortality in patients with diffuse large B cell lymphoma (DLBCL) receiving rituximab based chemotherapy : 111
Outcomes of Warfarin use in haemodialysis : 112
Short and long term neurological complications of thrombotic thrombocytopenic purpura (TTP) : 113
Demographic characteristics, prevalent comorbidities and treatment patterns: initial analysis from the United Kingdom Immune Thrombocytopenia (UK ITP) Registry : 114
A case of idiopathic acquired factor Xlll deficiency : 115
Using modified Wells rule and age adjusted D dimer in diagnosis of deep vein thrombosis : 116
The need for pre-test probability scoring in suspected deep venous thrombosis (DVT) in pregnancy identified by survey of practitioners; should the LEFt clinical prediction rule be adopted? : 117
Rare platelet disorder treatment and antibody screening: a North London network audit : 118
Adding rituximab to CODOX-M/IVAC chemotherapy in the treatment of HIVassociated Burkitt Lymphoma is safe when used with concurrent cART : 119
Burden of venothromboembolism and thromboprophylaxis at East Kent Hospitals NHS Foundation Trust in patients with myeloma treated with immunomodulatory drugs (IMid) containing regimens between 2009 and 2014: a retrospective study : 120
Prospective audit of rivaroxaban as thromboprophylaxis and treatment during myeloma therapy with immunomodulatory drugs (IMiDs) at East Kent Hospitals NHS Foundation Trust : 121
The frequency and characteristics of thrombotic events in adults and children treated for acute lymphoblastic leukaemia at a single centre : 122
MGUS Tracker - an alternative way of monitoring MGUS outside the haematology clinic : 123
Health-related quality of life impact of idelalisib in patients with relapsed chronic lymphocytic leukemia (CLL): phase 3 results : 124
Obinutuzumab (GA101) in combination with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or bendamustine for the first-line treatment of follicular non-Hodgkin lymphoma: final results from the maintenance phase of the phase Ib GAUDI study : 125
Patient-reported outcomes data from a phase 2 study of idelalisib in patients with refractory indolent B-cell non-hodgkin lymphoma (iNHL) : 126
An audit of compliance with the NICE guideline for the use of lenalidomide therapy in patients with myeloma : 127
Significant gender differences in the number and distribution of T cells in patients with mantle cell lymphoma : 128
Lenalidomide in relapsed/refractory aggressive lymphoma : 129
Use of PET-CT for patients with multiple myeloma at St Bartholomew's Hospital (SBH) : 130
Skeletal survey reported by experienced radiologist remains adequate as first-line radiological test for the majority of newlydiagnosed patients with multiple myeloma : 131
Rare, fulminant presentations of anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma - a case series : 132
Age but not BMI affects overall survival in Hodgkin lymphoma : 133
Outcomes from a single centre for patients with multiply relapsed myeloma treated with bendamustine containing regimens : 134
Estimation of the clinical benefit of idelalisib in double-refractory follicular lymphoma: Inference from uncontrolled study results : 135
Update on a phase 2 study of idelalisib in combination with rituximab in treatment-naïve patients ≥65 years with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) : 136
Outcome of transplantation in mantle cell lymphoma at University Hospitals Leicester - a single centre experience : 137
Follow up in de novo diffuse large B cell lymphoma patients treated with RCHOP: a new approach : 138
Audit of central nervous system (CNS) prophylaxis in patient with diffuse large B-cell lymphoma (DLBCL) : 139
Single centre experience of a Bruton's tyrosine kinase (BTK) specific inhibitor (ONO-4059) in relapsed mantle cell lymphoma (MCL) : 140
Single-agent ibrutinib for the treatment of mantle cell lymphoma (MCL): evaluating the link between durable response and quality of life (QoL) in the SPARK study : 141
Life-threatening bowel perforation while on thalidomide-based triplet regimen for multiple myeloma: a retrospective case series : 142
The North-West Amyloidosis Centre: Hub and spoke model of care for patients with amyloidosis in the United Kingdom (UK) : 143
Current use of nephelometric quantification of serum free light chains (FLCs) in the management of plasma cell dyscrasias, and the potential benefits of point-of-care testing : 144
A new trust protocol can reduce inappropriate requests for serum free light chain analysis : 145
ABVD and escalated BEACOPP for young advanced stage Hodgkin lymphoma : 146
Incidence of complex karyotype in CLL patients at King's College Hospital tertiary referral practice: implications for novel therapies : 147
Off trial use of brentuximab vedotin in Hodgkin lymphoma - a regional experience : 148
How does myeloma present in the 21st century? : 149
Single centre experience of R-mini CHOP for the treatment of elderly patients with diffuse large B-cell lymphoma : 150
Safety and efficacy of bendamustine use in patients with chronic lymphocytic leukaemia : 151
Risk factors associated with the development of infusion-related reactions (IRRs) in patients with chronic lymphocytic leukaemia (CLL) treated with anti-CD20 monoclonal antibodies (mAbs) in combination with chlorambucil: analysis of the prospective, randomised phase III CLL11 study dataset : 152
Ibrutinib in chronic lymphocytic leukaemia: experience from the East of the network : 153
Pattern of cytokine release in patients with chronic lymphocytic leukaemia treated with obinutuzumab and possible relationship with development of infusion related reactions (IRR) : 154
How accurate is the systemic anti-cancer therapy chemotherapy dataset for patients with lymphoproliferative disorders? : 155
Retrospective observational study of patients with relapsed/refractory myeloma treated with pomalidomide - the UK Experience : 156
Screening for and management of steroidinduced hyperglycaemia (SIH) in haematology outpatients : 157
Preliminary clinical experience on the efficacy and feasibility of a new combination regimen consisting of pixantrone (Pix), etoposide, and bendamustine with or without the addition of rituximab in patients with relapsed/refractory aggressive non-Hodgkin lymphomas (aNHL) : 158
Identifying MYC dysregulation in diffuse large B-cell lymphoma (DLBCL): correlation between immunohistochemistry (IHC) and fluorescencein-situ hybridisation (FISH) : 159
Implementing a remote surveillance programme for lymphoma patients : 160
Outcome for patients with relapsed/refractory lymphoma treated with gemcitabine and oxaliplatin with or without rituximab : 161
A survey of skeletal survey examinations in a tertiary centre : 162
Utility of skeletal survey in the assessment of symptomatic multiple myeloma in the current era : 163
Survival rates in elderly patients with diffuse large B-cell lymphoma over the last 20 years : 164
Real world efficacy of pomalidomide for relapsed myeloma - a multicentre restrospective study : 165
Evolution of the management of multiple myeloma in a district general hospital setting; a retrospective review of renal impairment and survival : 166
Comparison of ibrutinib and idelalisib + rituximab trials in patients with previously treated chronic lymphocytic leukaemia : 167
Factors influencing treatment initiation in patients with chronic lymphocytic leukaemia (CLL): evaluation of clinical characteristics in >27,500 newly-diagnosed patients : 168
Pharmacokinetics and safety of elotuzumab in combination with lenalidomide and dexamethasone in patients with multiple myeloma and various levels of renal function: updated results of a phase 1b study : 169
Haematologic and immunologic function and patient-reported outcomes for the phase 3 RESONATETM study of ibrutinib versus ofatumumab in relapsed/refractory chronic lymphocytic leukaemia/small lymphocytic lymphoma : 170
Pattern of use of anticoagulation and/or antiplatelet agents in patients with chronic lymphocytic leukaemia (CLL) treated with single-agent ibrutinib : 171
Results from the phase 2 RESONATETM-17 Trial: Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic leukaemia with 17p deletion : 172
Does CD5 have an effect on the expression of ROR1 in chronic lymphocytic leukaemia? : 173
Combination therapy with Falcarinol on human lymphoid leukaemia cell lines and increase the expression of cytochrome C, Bax and SMAC/ Diablo : 174
Antiproliferative and induction of apoptosis by pomegranate's anthocyanidins (delphinidin, cyanidin and pelargonidin) on lymphoid and myelopid leukaemia cell lines : 175
Subversion of PKCα signalling in B cell progenitors results in an upregulation of PKCβII expression and leukaemogenesis : 176
Next-generation sequencing in chronic lymphocytic leukaemia using Ion Torrent PGM shows evidence of chemotherapy-induced mutagenesis and a snowballing effect due to loss of p53/ATM-mediated DNA repair : 177
Chronic lymphocytic leukaemia (CLL) with t (1;6)(p35.3;p25.2) involving IRF4 and RCC1 and its effect on the regulation of IRF4 expression; a disease subtype associated with a poor outcome : 178
Advancing leukaemia and lymphoma therapy by ex-vivo compound screening : 179
T follicular helper cells in the follicular lymphoma microenvironment and germinal centres have a close spatial relationship with proliferating B cells, show features of synapse formation and are associated with expression of activation induced cytidine deaminase : 180
Optimisation of RNA extraction and RT-qPCR for the quantification of AID in archived FFPE biopsy samples: only two sections of 4 μm tissue are required : 181
Bruton's tyrosine kinase inhibition regulates chronic lymphocytic leukaemia cell migration by modulation of cell surface adhesion marker profile : 182
A novel B-cell receptor (BCR) internalisation assay reveals patients with adverse CLL have hyper-functional BCRs : 183
Delay in referral and diagnosis of chronic haeamatological malignancies in a tertiary hospital in Tanzania : 184
Primary imatinib resistance in chronic myeloid leukaemia patients: a critical analysis of BCR-ABL kinase domain mutations and clinical outcomes in a developing country : 185
Monitoring in the community - establishment of a service for patients with chronic myeloid leukaemia who have achieved a major molecular response : 186
Efficacy of azacitidine in the treatment of acute myeloid leukaemia (blasts >30%) in comparison to MDS : 187
Investigating differences in serum and plasma values in galactomannan testing, signal loss and sources of false positivity : 188
Local experience with ruxolitinib in primary and secondary myelofibrosis: an analysis of 10 patients treated with ruxolitinib in the Hull and East Yorkshire NHS Trust : 189
The risk of acute incapacitation at relapse of acute myeloid leukaemia (AML): mode of presentation and severity of symptoms : 190
Frequency and Management of Breakthrough Fungal Infections in Patients with AML/ALL on antifungal prophylaxis : 191
The effect on outcome of dose capping for obese patients undergoing induction chemotherapy for acute myeloid leukaemia : 192
Single centre experience in the use of pegylated interferon alpha for myeloproliferative neoplasms : 193
Azacitidine: Duration of treatment used in routine clinical practice in patients with myelodysplastic syndromes (MDS) in England : 194
Azacitidine use in North West London: an update : 195
Feasibility of recruitment of hydroxyurearesistant or intolerant ET and PV patients into the MAJIC study : 196
Baseline quality of life and symptom burden characteristics of patients intolerant to hydroxyurea: Preliminary results from the MAJIC Trial : 197
Nilotinib as first line tyrosine kinase inhibitor treatment for newly diagnosed chronic myeloid leukaemia patients: a preliminary review of the clinical presentation and outcomes in a developing country : 198
Convenient care for patients: A real world evaluation to describe the NHS impact of administering velcade® (bortezomib) in a home setting for patients with multiple myeloma : 199
Factors affecting response to erythropoietin in low risk MDS patients : 200
Alternate day lenalidamide as a well-tolerated and cost-effective treatment in multiple myeloma : 201
Utility of integrated diagnostic reporting (IDR) in patients with myeloid malignancies : 202
Ruxolitinib withdrawal syndrome : 203
CALR mutations in myeloproliferative neoplasm related splanchnic vein thrombosis : 204
Challenges in ETV6-ABL1 positive CML treatment and monitoring: a case report : 205
How well are patients with myeloproliferative neoplasms assessed for cardiovascular risk: an audit report : 206
Single centre experience of treating three cases of relapsed/refractory BRAF mutated Erdheim Chester disease (ECD) with vemurafenib : 207
Prevalence and clinical impact of IDH1 and IDH2 mutations among cytogenetically normal Egyptian acute myeloid leukaemia patients : 208
Prognostic impact of CD25, and CD123 expression in acute myeloid leukaemia patients : 209
Stimulation of TLR-4 promotes increased proliferation and resistance to NK-induced apoptosis in acute myeloid leukaemia : 210
MUC1 suppresses MiR34a expression leading to an expansion of myeloid-derived suppressor cells (MDSCs) in acute myeloid leukaemia : 211
Perturbation of JAK2-dependent transcriptional and inflammatory gene expression in polycythaemia vera : 212
Using induced pluripotent stem cells as a replacement for in-vivo models to screen novel therapies which target leukaemic stem cells in CML : 213
The molecular and therapeutic relevance of SF3B1 in myelodysplastic syndrome : 214
Modulation of mutated cohesin complex gene expression in acute myeloid leukaemia cell lines : 215
The role of Notch signalling in a blast crisis chronic myeloid leukaemia phenotype : 216
Telomere length analysis provides unique insights into the pathogenesis of MDS and AML and is associated with a worse overall survival in MDS but not AML : 217
Dual PI3K/mTOR inhibition in combination with inhibition of autophagy to improve treatment response for BCR-ABL independent mechanisms of TKI-resistance in CML : 218
Expression of the transcription factors FOG1, FLI-1 and GATA1 in the peripheral blood of essential thrombocythaemia patients : 219
Seroprevalence of undiagnosed transfusion transmissible infections (HIV, hepatitis B and C and syphilis) in donated blood in National Blood Banks, Khartoum, Sudan : 220
Real time audit of transfusion practice is very different from standard audits : 221
Audit into HLA-typing and HLA-sensitisation in patients with inherited platelet disorders attending the West of Scotland Haemophilia Comprehensive Care Centre : 222
Blood transfusion and the intensive care unit : 223
The impact of maternal allo-antibodies on the clinical outcomes of foetuses/neonates at Barts Health NHS Trust : 224
Red cell depletion in automated red cell exchange: a safe and effective method of exchange transfusion whilst reducing blood usage : 225
Incidence of Rh and Kell blood group antigens among blood donors in Qatar : 226
Consent to long-term multiple blood transfusions for patients admitted to the haematology ward: a complete audit cycle and quality improvement project : 227
The impact of poor haematology sampling and labelling on the decision to transfuse patients : 228
Traditional audit methods to assess blood component use: limitations of time and efficiency : 229
Successful renal transplantation in Jehovah's Witnesses -shouldn't we apply our approach to blood refusers to all patients, to reduce risks associated with blood transfusions? : 230
Contribution of the British Bone Marrow Registry (BBMR) to the UK transplant activity in 2007 and investigation of final donors in this year : 231
The use and outcomes of prothrombin complex concentrate in a district general hospital : 232
High-dose chemotherapy and autologous stem cell transplantation is feasible and effective for patients with human immunodeficiency virus and primary central nervous system lymphoma : 233
Engraftment post melphalan autologous stem cell transplant (ASCT) for multiple myeloma (MM): Granulocyte colony stimulating factor (G-CSF) initiation correlates with neutrophil recovery independent of CD34 dose: a study from 3 United Kingdom Centres : 234
Full term pregnancy in patient with sickle cell disease and a renal transplant : 235
An audit showing the effect of modern myeloma treatments on service delivery: How will day units cope with the increase in demand in the future? : 236
The need for independent prescribers on a busy haematology day unit: an audit of the quantity and type of drugs prescribed on an ad-hoc basis : 237
High recruitment into interventional clinical trials is possible in the setting of a district general trust (DGT): results of a short prospective audit : 238
Auditing a new myeloma clinic : 239
An audit showing how we improved waiting times in the Cardiff Lymphoma Clinic : 240
Clinical trials: A survey of recruitment figures, screening failures and interventions used to increase recruitment over 4 year period in a teaching hospital : 241
Reduction of depression and anxiety scores following psychotherapy in haematooncological patients : 242
Effects of the 2013 MHRA update on codeine use: a retrospective study of admissions to hospital with an acute vaso-occlusive pain crisis in children with sickle cell disease : 243
Audit of low molecular weight heparin dosing and anti-Xa monitoring in paediatric patients in the University Hospitals of Leicester : 244
Prospective audit of the use of healthcare passports for patients with sickle cell disease : 245
Radiologic evaluation of osteonecrosis of femoralhead in homozygous sickle cell disease : 246
Iron deficiency anaemia during pregnancy: the treatment approaches and outcomes : 247
A review of the services available to support people with sickle cell disease in South London : 248
Use of analgesia in sickle cell crisis at Volta Regional Hospital, Ho, Ghana : 249
Line colonisation in automated red cell exchange transfusion for sickle cell anaemia : 250
Audit into the management of acute painful sickle crisis in the first 2 hours of admission and the use of patient-controlled analgesia : 251
A cross sectional survey to explore GP involvement in the management of sickle cell disease in primary care in City and Hackney : 252
Mortality in adult with sickle cell disease. Sixteen years’ experience in a single centre in London : 253
An investigation of barriers affecting the use of hydroxycarbamide in the adult sickle cell disease population : 254
Haemoglobinopathy screening pathways and attitudes to opportunistic screening for haemoglobinopathies : 255
Exploring the psychosocial implications of living and coping with sickle cell crisis: an interpretative phenomenological analysis : 256
Safety and efficacy of elective automated red cell exchange transfusion programmes for patients with sickle cell disease at a single centre : 257